Unknown PHASE2 INTERVENTIONAL 2-arm NCT03399955

Short Course Regimens for Treatment of PKDL (Sudan)

An Open Label, Randomized, Parallel Arm Clinical Trial of Two Regimens to Assess the Safety and Efficacy for Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) Patients in Sudan

Sponsor: Drugs for Neglected Diseases

Conditions PKDL - Post-Kala-Azar Dermal Leishmanioid

Interventions Ambisome Miltefosine Paromomycin

Updated 8 times since 2018 Last updated: Jan 15, 2020 Started: May 9, 2018 Primary completion: May 9, 2021 Completion: May 1, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on PKDL - Post-Kala-Azar Dermal Leishmanioid, this trial is ongoing. The trial is conducted by Drugs for Neglected Diseases and has accumulated 8 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jun 2022 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jan 2021 — Jun 2022 [monthly]

Recruiting PHASE2
Feb 2020 — Jan 2021 [monthly]

Recruiting PHASE2

▶ Show 3 earlier versions

Aug 2018 — Feb 2020 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jun 2018 — Aug 2018 [monthly]

Not Yet Recruiting PHASE2
Feb 2018 — Jun 2018 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Drugs for Neglected Diseases

Data source: Drugs for Neglected Diseases

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Doka, Sudan